- Home
- EDTK vs BIAF Comparison
EDTK vs BIAF Comparison
Compare EDTK & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- BIAF
- Stock Information
- Founded
- EDTK 2013
- BIAF 2014
- Country
- EDTK China
- BIAF United States
- Employees
- EDTK N/A
- BIAF N/A
- Industry
- EDTK Other Consumer Services
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EDTK Real Estate
- BIAF Health Care
- Exchange
- EDTK Nasdaq
- BIAF Nasdaq
- Market Cap
- EDTK 15.2M
- BIAF 12.2M
- IPO Year
- EDTK 2020
- BIAF 2022
- Fundamental
- Price
- EDTK $0.96
- BIAF $0.28
- Analyst Decision
- EDTK
- BIAF Hold
- Analyst Count
- EDTK 0
- BIAF 1
- Target Price
- EDTK N/A
- BIAF N/A
- AVG Volume (30 Days)
- EDTK 6.8K
- BIAF 9.1M
- Earning Date
- EDTK 06-13-2025
- BIAF 05-15-2025
- Dividend Yield
- EDTK N/A
- BIAF N/A
- EPS Growth
- EDTK N/A
- BIAF N/A
- EPS
- EDTK N/A
- BIAF N/A
- Revenue
- EDTK $624,365.00
- BIAF $8,809,228.00
- Revenue This Year
- EDTK N/A
- BIAF N/A
- Revenue Next Year
- EDTK N/A
- BIAF $20.00
- P/E Ratio
- EDTK N/A
- BIAF N/A
- Revenue Growth
- EDTK N/A
- BIAF 78.40
- 52 Week Low
- EDTK $0.80
- BIAF $0.16
- 52 Week High
- EDTK $1.27
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- EDTK 51.78
- BIAF 46.46
- Support Level
- EDTK $0.90
- BIAF $0.24
- Resistance Level
- EDTK $0.94
- BIAF $0.32
- Average True Range (ATR)
- EDTK 0.04
- BIAF 0.06
- MACD
- EDTK 0.00
- BIAF 0.01
- Stochastic Oscillator
- EDTK 78.18
- BIAF 28.07
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.